**Table E1**. Potential predictors of an adequate EBUS sample for PD-L1 testing.

|  |  |
| --- | --- |
| **Variable** | **Univariable analysis**  |
| **p-value** | **OR** | **95% CI** |
| **NSCLC subtype (adenocarcinoma vs. other)** | 0.894 | 0.90  | (0.18-4.50) |
| **Disease stage (I-II vs. III-IV)** | 0.101 | 0.23  | (0.04-1.33) |
| **Site of sample (hilar vs. mediastinal)** | 0.275 | 0.48  | (0.13-1.79) |
| **Number of needle passes (continuous variable)** | 0.177 | 0.72  | (0.44-1.16) |
| **Number of needle passes (>3 vs. ≤3)** | 0.279 | 0.46  | (0.11-1.88) |
| **Availability of ROSE** | 0.461  | 0.43  | (0.05-4.07) |